The table below shows Xeris Biopharma Holdings, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$83.13M
$74.38M
$71.54M
$60.12M
$54.27M
$48.06M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$8.78M
$7.48M
$8.05M
$7.75M
$5.89M
$5.76M
SG&A
XERS annual revenue (10-K history)
Xeris Biopharma Holdings, Inc. reported annual revenue of $291.85M for fiscal year 2025. That is up 43.7% from $203.07M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $20.43M (FY 2020) to $291.85M. Figures come from the company's audited annual reports as filed with the SEC.